



# Journal of Frontiers in Multidisciplinary Research

## Implementing Corrective and Preventive Action Strategies to Achieve Sustainable Clinical Trial Compliance

Chisom Ezeanochie <sup>1\*</sup>, Opeoluwa Oluwanifemi Akomolafe <sup>2</sup>, Christiana Adeyemi <sup>3</sup>

<sup>1</sup> HealthPlus Limited, Nigeria

<sup>2</sup> Amazing Grace Adult Home, Akure, Ondo State, Nigeria

<sup>3</sup> Lagos State University Teaching Hospital, Nigeria

\* Corresponding Author: **Chisom Ezeanochie**

---

### Article Info

**E-ISSN:** 3050-9726

**P-ISSN:** 3050-9718

**Volume:** 02

**Issue:** 02

**July – December 2021**

**Received:** 23-08-2021

**Accepted:** 25-09-2021

**Published:** 26-10-2021

**Page No:** 239-256

### Abstract

The implementation of corrective and preventive action (CAPA) strategies has become a cornerstone in maintaining sustainable clinical trial compliance within the evolving regulatory landscape. Clinical trials are complex endeavors, often involving multiple stakeholders, diverse geographies, and intricate regulatory requirements. As trials expand globally, ensuring consistent adherence to Good Clinical Practice (GCP) and international guidelines requires structured mechanisms to identify, address, and prevent compliance deficiencies. This paper explores how systematic CAPA strategies can be deployed to improve operational efficiency, mitigate risks, and strengthen long-term sustainability in clinical trial compliance. Corrective actions focus on remediating nonconformities such as protocol deviations, data integrity issues, or delayed reporting of adverse events, while preventive actions proactively address underlying causes to reduce recurrence. A robust CAPA framework integrates root cause analysis, cross-functional collaboration, and continuous monitoring to ensure accountability and regulatory alignment. By embedding CAPA processes into quality management systems, organizations can enhance transparency, improve documentation practices, and foster a culture of continuous improvement. Moreover, digital innovations such as risk-based monitoring, centralized data analytics, and automated reporting systems are transforming CAPA implementation, enabling real-time detection of compliance risks and timely intervention. These tools not only streamline documentation and communication but also support predictive modeling to anticipate potential challenges before they escalate. Case examples from oncology and rare disease trials demonstrate that CAPA-driven approaches significantly reduce protocol violations, improve patient safety oversight, and enhance data credibility. Sustainable compliance is achieved when CAPA strategies transcend reactive measures and evolve into preventive frameworks that promote resilience, adaptability, and ethical rigor. For sponsors, contract research organizations, and regulatory bodies, CAPA represents a dynamic mechanism to safeguard patient rights, ensure scientific validity, and uphold public trust in clinical research. This paper concludes that embedding CAPA into organizational culture and leveraging advanced technologies are critical to achieving lasting compliance in multi-site, multi-country clinical trials.

**DOI:** <https://doi.org/10.54660/JFMR.2021.2.2.239-256>

**Keywords:** Corrective Action, Preventive Action, CAPA, Clinical Trial Compliance, Patient Safety, Regulatory Adherence, Data Integrity, Risk-Based Monitoring, Quality Management, Sustainable Compliance

---

### 1. Introduction

Multi-site clinical trials operate across diverse healthcare systems, languages, and regulatory expectations, creating uneven processes, variable site maturity, and fragmented data flows. These factors heighten the risk of protocol deviations, delayed adverse event reporting, inconsistent informed-consent practices, and preventable data integrity issues. Vendor ecosystems, hybrid/decentralized procedures, and rapid technology adoption further complicate oversight, while traditional, document-heavy quality controls can mask root causes rather than resolve them. In this context, a disciplined approach is required to convert

scattered findings into systemic learning and durable performance gains that withstand staff turnover, study amendments, and geographic expansion (Haw, *et al.*, 2017, Hurley, *et al.*, 2016, Hurley, *et al.*, 2018).

Corrective and preventive action (CAPA) provides that discipline. Corrective actions eliminate detected nonconformities; preventive actions address underlying causes to stop recurrence elsewhere in the system. Risk-based quality management (RBQM) complements CAPA by prioritizing risks that matter most to patient safety and data reliability, using prospectively defined critical-to-quality factors, signals, and key risk indicators to direct attention and resources. Sustainable compliance is the state in which CAPA and RBQM are embedded in everyday operations supported by clear governance, fit-for-purpose digital tools, transparent metrics, and continuous feedback so that consistency, resilience, and ethical rigor are preserved across sites and over time (Arora, Maurya & Kacker, 2017, Uwaifo & John-Ohimai, 2020).

The objectives of this work are threefold: first, to reduce recurrence of noncompliance by moving from symptom-level fixes to root-cause-driven, system-level solutions that are prioritized by risk and verified for effectiveness; second, to protect patients by ensuring timely detection, escalation, and resolution of safety-relevant issues, coupled with preventive controls that safeguard consent quality, safety reporting, and protocol conduct; and third, to strengthen data integrity by designing controls that improve accuracy, completeness, and traceability at the source, supported by monitoring strategies and analytics that detect anomalies early. Together, these objectives position CAPA and RBQM as mutually reinforcing mechanisms that transform compliance from a reactive obligation into a proactive, learning-oriented capability suited for complex, global clinical research (Akpan, *et al.*, 2017, Bankole, Nwokediegwu & Okiye, 2020).

## 2. Methodology

This study implements a corrective and preventive action (CAPA) operating model that embeds compliance-by-design into clinical trial conduct and uses continuous digital risk sensing to keep trials sustainably aligned with GCP and protocol requirements. We begin by defining governance and objectives with a cross-functional quality team that includes clinical operations, data management, pharmacovigilance, biostatistics, informatics, and site representatives. Critical-to-quality factors are derived from the protocol, with patient safety and primary endpoint integrity prioritized. Roles, escalation thresholds, and decision rights are codified in a RACI and linked to the sponsor's quality management system. A unified data fabric is then established to enable near-real-time monitoring across eSource/EHR integrations, eConsent, ePRO/telehealth streams, imaging and lab feeds, and safety databases (Fneish, Schaarschmidt & Fortwengel, 2021). Metadata capture, immutable audit trails, device management, and data lineage are enforced to support traceability and audit readiness while permitting decentralized and hybrid trial workflows. Telemedicine capabilities are configured using approved platforms to support remote visits, follow-ups, and safety checks; standard operating procedures cover scheduling, identity verification, contingency planning for connectivity, and documentation of clinical decision-making.

Continuous risk sensing is operationalized through risk-based


monitoring (RBM) with key risk indicators for enrollment variability, protocol deviation density, data latency and query burden, AE/SAE reporting timeliness, and remote-visit completion. Streamed signals are analyzed by supervised and unsupervised machine learning models to detect outliers and emergent patterns related to site performance, participant safety, and data quality. To ensure transparent decision-making, explainable AI methods are layered on model outputs to show feature importance, local contribution scores, and confidence intervals, enabling reviewers to validate whether signals reflect true process issues versus data artifacts. Automated triage rules route alerts by severity to the appropriate owners while human review boards adjudicate ambiguous cases using pre-defined criteria that balance sensitivity with workload (Hopkins, Burns & Eden, 2013, K Gohagan, *et al.*, 2015, Obodozie, 2012).

When a material nonconformance or risk signal is confirmed, structured root-cause analysis is performed using 5 Whys, Ishikawa diagrams, and where digital footprints are available process mining to visualize actual versus intended workflows. Root causes are categorized across people (skills, cognition, bandwidth), process (unclear SOPs, handoff gaps, documentation friction), technology (configuration errors, access control, integration failures), policy (protocol ambiguity, vendor contracts), data (missingness, drift, bias), and environment (connectivity, language, socio-cultural fit). Corrective and preventive actions are then planned in a single CAPA charter that specifies problem statements, measurable objectives, action owners, resources, timelines, and verification evidence (Erickson, *et al.*, 2003, Hungbo, Adeyemi & Ajayi, 2019, Uwaifo, *et al.*, 2018). Corrective actions may include immediate containment, protocol clarifications, safety follow-ups, data backfills, or vendor hotfixes; preventive actions may include SOP redesign, checklist insertion at failure points, automation of high-risk manual steps, competency-based training with observed practice, and user-centered tweaks to telehealth and ePRO workflows. All changes pass through formal change control with impact assessment on data integrity, participant safety, and regulatory commitments.

Implementation proceeds in controlled pilots at sentinel sites to de-risk scale-up. Sites receive coaching, job aids, and brief "micro-learning" modules aligned to the specific failure modes encountered (for example, improving remote blood-pressure capture reliability or standardizing AE intake scripts during telehealth). Configuration evidence screen captures, access logs, and parameter exports is stored with the CAPA record. Verification of implementation uses checklists to confirm that actions have been executed as intended, and only then are effectiveness criteria activated. Effectiveness is assessed over an a priori observation window by tracking improvement against baselines on deviation recurrence, data quality indices, query resolution time, AE/SAE timeliness, ePRO completion rates, consent re-verification success, and audit/inspection outcomes (Adeyemi, *et al.*, 2021, Cruz Rivera, *et al.*, 2021, Giwah, *et al.*, 2021). Statistical process control charts and risk heatmaps visualize trend stabilization or residual risk. If targets are met, the CAPA is closed; lessons learned, updated SOPs, and reusable analytics components are promoted to the enterprise quality knowledge base and linked to onboarding curricula. If targets are missed, the CAPA remains open and is escalated for deeper analysis, additional resourcing, or protocol/vendor remediation, with rapid communication to governance bodies and, when

applicable, regulators and ethics committees. Throughout, privacy, security, and equity are embedded. Role-based access and zero-trust principles govern data flows across vendors, sites, and devices; all telehealth and remote-monitoring components comply with encryption and consent requirements, and performance is segmented by geography, language, and demographic factors to detect inequitable burdens or safety gaps. Human-in-the-loop review remains mandatory for safety-critical decisions, with explainability artifacts captured alongside decisions to support inspection. Sustainability is achieved by institutionalizing this CAPA loop as a standing quality service: automated signal detection, routine quality councils, and a digital CAPA registry ensure

continuity across studies (Hedt-Gauthier, *et al.*, 2017, Lewis, *et al.*, 2014, Pillai, *et al.*, 2018). The model's emphasis on remote care enablement, health-data analytics, and explainable decision support leverages current evidence on telemedicine, predictive analytics for chronic and infectious diseases, elderly and primary-care strengthening, cybersecurity and IoT reliability, and CAPA best practices from pharmaceutical quality science. By integrating these strands into a single, monitored loop sense, understand, fix, prevent, and learn the study drives durable compliance, higher data integrity, and faster, safer oncology and non-oncology trial execution.



**Fig 1:** Flowchart of the study methodology

## 2.1. Regulatory & QMS Foundations

Regulatory frameworks and quality management systems form the backbone of corrective and preventive action (CAPA) strategies in clinical research. Sustainable clinical trial compliance requires that CAPA not be viewed as an isolated procedure but rather as an integrated part of a broader system of regulatory adherence, operational discipline, and continuous improvement. The foundation is built upon

international guidelines such as ICH E6(R3) and ICH E8(R1), regional and national regulatory codes from authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA), and global standards promoted by the World Health Organization (WHO). These frameworks create the expectations against which compliance is measured and

provide the scaffolding into which CAPA processes must be embedded for them to be effective and sustainable (Adeyemo, Mbata & Balogun, 2021, Barnes, *et al.*, 2021, de Sá Vale, 2021).

ICH E6(R3), the Good Clinical Practice (GCP) guideline currently undergoing modernization, emphasizes quality by design and risk-based approaches. It positions CAPA as an essential component of managing deviations, ensuring data credibility, and protecting participant rights. By requiring sponsors and investigators to not only identify nonconformities but also address root causes, ICH E6(R3) encourages a proactive mindset that aligns perfectly with CAPA philosophy. Similarly, ICH E8(R1) broadens the

quality framework by promoting critical-to-quality factors at every stage of a clinical trial (Elebe & Imediogwu, 2020, Eneogu, *et al.*, 2020). These include ensuring robust informed consent processes, reliable endpoint assessment, and accurate data capture. In practice, these guidelines mean that CAPA is not limited to fixing an isolated protocol deviation but extends to embedding preventive mechanisms that strengthen the entire trial lifecycle. Together, E6(R3) and E8(R1) create an expectation of continuous oversight, accountability, and systemic learning, which CAPA processes directly operationalize. Figure 2 shows CAPA management system presented by Raj, 2016.




Fig 2: CAPA management system (Raj, 2016).

The FDA provides further regulatory specificity through its Title 21 of the Code of Federal Regulations. Parts 50 and 56 govern informed consent and Institutional Review Boards (IRBs), underscoring the ethical obligations that CAPA systems must safeguard. Part 312 regulates Investigational New Drug applications, ensuring that deviations in protocol conduct, adverse event reporting, or data submission are corrected and prevented from recurring. Part 11, focusing on electronic records and electronic signatures, ensures that digital CAPA processes meet standards of integrity, auditability, and security (Awe, Akpan & Adekoya, 2017, Isa & Dem, 2014). These regulations emphasize the expectation that sponsors and contract research organizations (CROs) will maintain systems to detect noncompliance, take corrective actions, and prevent recurrence whether the issue arises from inadequate informed consent documentation, late safety reporting, or flaws in electronic data capture systems. CAPA thus becomes the mechanism by which regulatory requirements are translated into operational practice and documented evidence of compliance (Beck, *et al.*, 2020, Curtis, *et al.*, 2020, Uwaifo & Favour, 2020).

Regional regulators reinforce these principles with their own expectations. The EMA and MHRA emphasize data integrity, patient safety, and inspection readiness. Their guidance documents frequently cite the ALCOA+ principles Attributable, Legible, Contemporaneous, Original, and Accurate, plus Complete, Consistent, Enduring, and

Available as the gold standard for data quality. CAPA frameworks must therefore not only address the immediate cause of a deviation but also ensure that the data lifecycle remains consistent with ALCOA+ from source to submission. For example, if an inspection reveals backdated entries in a site log, the corrective action may be retraining staff on proper contemporaneous documentation, but the preventive action must involve system redesigns such as electronic timestamping, routine data quality checks, and enhanced oversight mechanisms. In this way, ALCOA+ becomes both a benchmark for quality and a driver of CAPA system design (Agrafiotis, *et al.*, 2018, Bhatt, 2011, Ellenberg, Fleming & DeMets, 2019).

The WHO provides a global perspective, particularly relevant in multi-country and resource-diverse settings. Its guidance underscores the need for harmonization of GCP practices, especially in emerging research regions where infrastructure, training, and oversight may be uneven. CAPA strategies implemented in such environments must account for local capacity gaps while still aligning with international standards. This means developing culturally appropriate training modules, strengthening local SOPs, and leveraging mentorship to embed sustainable preventive practices. By grounding CAPA in WHO-aligned frameworks, sponsors and CROs can ensure that compliance is not merely a matter of satisfying regulators in high-income countries but is also achievable and sustainable across all global trial sites (Essien,


*et al.*, 2020, Nicholson, *et al.*, 2020, Oluyemi, Akintimehin & Akomolafe, 2020).

Embedding CAPA within sponsor and CRO quality management systems is where regulatory requirements translate into daily practice. A CAPA system must be integrated into the broader QMS, alongside deviation management, change control, training, audit, and vendor oversight. Within this structure, CAPA serves as the connective tissue that links findings from audits, inspections, and routine monitoring to systemic improvement. For sponsors, this may involve establishing CAPA boards or quality councils that review issues, approve root cause analyses, and track effectiveness. For CROs, it requires alignment with sponsor expectations while ensuring that operational teams have the tools, resources, and training to implement CAPA effectively (Atobatele, Hungbo & Adeyemi, 2019, Gong, *et al.*, 2017, Uwaifo, *et al.*, 2019). At the site level, standard operating procedures must explicitly outline how deviations are reported, investigated, corrected, and prevented, creating a consistent loop of accountability across the clinical trial ecosystem.

A mature CAPA system within a QMS also requires documentation rigor and traceability. Every CAPA must include a clear problem statement, a root cause analysis, a corrective plan, a preventive plan, defined timelines, and a verification of effectiveness. This ensures that regulators reviewing trial records can trace the lifecycle of an issue from

detection to closure. It also ensures that organizations can analyze CAPA trends across studies, identifying systemic weaknesses such as recurring consent errors, data entry delays, or insufficient safety reporting. In this way, CAPA contributes not only to compliance but also to organizational learning and continuous quality improvement (Giwah, *et al.*, 2020, Oluyemi, Akintimehin & Akomolafe, 2020, Özenver & Efferth, 2020).

The sustainability of clinical trial compliance depends on embedding CAPA principles into organizational culture rather than treating them as bureaucratic obligations. This involves training staff to see deviations not as failures but as opportunities for systemic improvement. It requires leadership commitment to resourcing CAPA adequately, ensuring that preventive measures such as SOP updates, process redesigns, and technology upgrades are prioritized alongside corrective actions (Alemayehu, Mitchell & Nikles, 2018, Barger, *et al.*, 2019, Friedman, *et al.*, 2015). It also demands transparency, with lessons learned from one trial shared across portfolios and geographies to prevent recurrence elsewhere. When CAPA is embedded in QMS and site SOPs in this manner, it evolves from a reactive tool into a proactive, preventive mechanism that strengthens resilience across the clinical trial enterprise. Figure 3 shows the procedure for performing corrective/preventive action presented by Marković, 2019.



**Fig 3:** Procedure for performing corrective/preventive action (Marković, 2019).

In sum, regulatory frameworks such as ICH E6(R3), ICH E8(R1), FDA regulations, EMA/MHRA guidance, and WHO standards establish the expectations for compliance, while ALCOA+ principles define the standard of data integrity. Embedding CAPA within sponsor, CRO, and site QMS transforms these expectations into practical, sustainable processes that detect, correct, and prevent noncompliance. By integrating CAPA into daily operations and aligning it with


regulatory and ethical frameworks, organizations not only protect participants and ensure data credibility but also create a culture of continuous improvement. This culture, in turn, drives sustainable compliance, ensuring that multi-site clinical trials remain credible, ethical, and resilient in an increasingly complex global research environment (Adeyemo, Mbata & Balogun, 2021, Oluyemi, Akintimehin & Akomolafe, 2021).

## 2.2. Risk-Based Quality Management (RBQM) Integration

Risk-based quality management (RBQM) provides the conceptual and operational framework through which corrective and preventive action (CAPA) strategies achieve their fullest potential in clinical trials. Modern clinical research is characterized by increasing complexity, global dispersion, and dependence on digital technologies. These factors create multiple points where errors, deviations, and systemic failures can emerge. Without a structured mechanism for anticipating, prioritizing, and addressing risks, CAPA becomes reactive and fragmented. RBQM ensures that CAPA processes are deployed in a strategic manner, targeting the issues most likely to compromise patient safety, data integrity, and regulatory compliance. By embedding CAPA within an RBQM framework, clinical research organizations move beyond firefighting to cultivate resilience, efficiency, and sustainable compliance (Komi, *et al.*, 2021, Merotiwon, Akintimehin & Akomolafe, 2021).

The foundation of RBQM integration lies in risk planning, which requires systematic identification, assessment, and prioritization of potential vulnerabilities. The Risk Assessment and Categorization Tool (RACT) is one widely

adopted instrument that enables trial teams to evaluate study complexity, therapeutic area sensitivity, data criticality, and operational feasibility. It helps stakeholders distinguish between activities that directly affect primary endpoints or patient safety and those of secondary importance. Complementary methodologies such as Failure Mode and Effects Analysis (FMEA) and hazard analysis deepen this evaluation by quantifying the probability and impact of potential failures (Hoffmann & Rohe, 2010, Macefield, *et al.*, 2013, Nchinda, 2002). For example, an FMEA exercise might reveal that delayed serious adverse event (SAE) reporting carries both a high likelihood of occurrence in multi-country trials and a severe impact on patient safety and regulatory compliance. CAPA processes are then calibrated accordingly, ensuring that preventive measures such as real-time safety signal detection and reinforced investigator training are prioritized. Through such systematic risk planning, CAPA becomes proactive rather than merely corrective, addressing root causes before they manifest as deviations or inspection findings. Figure 4 shows process to develop and continually improve a quality control plan (Nichols, 2011).



**Fig 4:** Process to develop and continually improve a quality control plan (Nichols, 2011).

Key risk indicators (KRIs) and key performance indicators (KPIs) serve as the metrics that connect RBQM and CAPA. KRIs highlight potential areas of vulnerability such as high rates of protocol deviations per site, late data entry, or missing informed consent forms while KPIs measure the effectiveness of CAPA interventions in addressing those risks. For instance, if a KRI shows a rising trend in late SAE reporting, the CAPA system may implement enhanced safety training, automated alerts, and escalation pathways. KPIs then measure whether the rate of timely SAE submissions improves in the subsequent monitoring periods (Atobatele, Hungbo & Adeyemi, 2019, Hamilton & Yano, 2017, Onyeji & Sanusi, 2018). By systematically linking KRIs to CAPA triggers and KPIs to CAPA outcomes, organizations create a closed-loop system of continuous improvement that is both measurable and sustainable. This approach ensures that

CAPA is not only reactive but also a driver of performance optimization across the trial portfolio.

Signal detection and escalation pathways further enhance this integration by ensuring that emerging issues are acted upon swiftly and consistently. In practice, signal detection involves analyzing disparate data streams including clinical data, operational metrics, and safety reports to identify patterns suggestive of risk. Escalation pathways define who is responsible for reviewing these signals, what thresholds trigger formal CAPA initiation, and how communication flows across sponsor, CRO, and site levels (Ajayi & Akanji, 2021, Chianumba, *et al.*, 2021). For example, an unusual spike in early patient withdrawals may trigger an escalation pathway that involves a cross-functional review team conducting a root cause analysis. If the issue is traced to overly burdensome visit schedules, corrective action may

involve protocol amendment, while preventive action could entail re-evaluating patient burden during study design phases of future trials. Escalation pathways thus ensure that CAPA responses are not only swift but also aligned with organizational governance structures, reducing variability and enhancing accountability.

One of the defining advantages of integrating RBQM with CAPA is its capacity to scale across diverse geographies and therapeutic areas. Multi-country oncology trials, for example, often face challenges in consistent safety reporting and protocol adherence due to varying levels of site maturity. By applying risk planning tools such as RACT and FMEA at study initiation, sponsors can identify sites at higher risk of noncompliance and direct targeted CAPA interventions such as additional training or intensified monitoring before issues occur. Similarly, centralized monitoring systems can detect cross-site anomalies in laboratory test turnaround times or adverse event underreporting, prompting immediate corrective and preventive actions (Essien, *et al.*, 2019, Olaniyan, Ale, & Uwaifo, 2019, Taiwo, 2015). The integration ensures that CAPA does not function in silos but rather as part of a harmonized global quality management system.

Moreover, RBQM integration enhances regulatory confidence in CAPA systems. Regulatory authorities such as the FDA, EMA, and MHRA increasingly expect sponsors to demonstrate risk-based approaches in trial oversight. Inspections often focus not only on the existence of CAPA systems but also on their integration with risk management frameworks. Organizations that can demonstrate proactive risk planning, data-driven monitoring, and evidence-based CAPA effectiveness are better positioned to withstand regulatory scrutiny. This is especially relevant under evolving guidelines such as ICH E6(R3), which emphasize quality by design and risk-based approaches to compliance. By aligning CAPA with RBQM, organizations ensure that their compliance posture is not only reactive to deviations but also anticipatory, systematic, and regulatorily aligned (Armstrong, *et al.*, 2009, Fenlon, *et al.*, 2013, Uwaifo, 2020). The cultural dimension of RBQM-CAPA integration should not be overlooked. Sustainable compliance requires that trial teams, from senior executives to site coordinators, internalize the principle that risks are not failures but opportunities for improvement. This cultural shift fosters transparency in reporting deviations, openness in conducting root cause analyses, and accountability in implementing preventive measures. Escalation pathways function effectively only when staff feel empowered to raise issues without fear of punitive consequences. Similarly, KRIs and KPIs deliver value only when organizations commit to learning from them, rather than treating them as box-checking exercises (Elebe & Imediegwu, 2020, Imediegwu & Elebe, 2020). Embedding this mindset within organizational culture transforms CAPA from a bureaucratic requirement into a strategic enabler of trial excellence.

In conclusion, risk-based quality management provides the structure and discipline that elevate corrective and preventive action strategies from reactive fixes to systemic safeguards of sustainable clinical trial compliance. Risk planning tools such as RACT, FMEA, and hazard analysis identify and prioritize vulnerabilities. Centralized monitoring ensures real-time detection and response to anomalies. KRIs and KPIs link risks to actions and outcomes, creating measurable accountability. Signal detection and escalation pathways

operationalize swift and consistent responses (Awe, 2017, Menon, *et al.*, 2018). Together, these elements ensure that CAPA is not an isolated process but an integrated component of a proactive, data-driven, and globally harmonized quality management system. By embedding CAPA within RBQM, clinical research organizations achieve not only compliance but also resilience, efficiency, and credibility in an increasingly complex and demanding regulatory landscape.

### 2.3. CAPA Lifecycle & Process Design

The lifecycle and process design of corrective and preventive action (CAPA) in clinical research is the mechanism through which organizations translate deviations, findings, and risks into sustainable compliance and continuous improvement. CAPA provides a structured pathway for moving from problem detection to problem resolution, ensuring that nonconformities are not only corrected but prevented from recurring. This lifecycle begins with the detection and logging of issues, proceeds through containment and root cause analysis, advances to corrective and preventive action planning and implementation, and concludes with verification of effectiveness (VoE) and closure. Each phase is critical, and together they form the backbone of sustainable compliance in multi-site, multi-country clinical trials (Rosemann, 2017, Shyr & Yang, 2008, Thornicroft, *et al.*, 2012).

Detection and logging represent the entry point of the CAPA process. Clinical trials produce a wealth of information from monitoring visits, internal audits, external inspections, deviation reports, and safety surveillance. Any of these sources can reveal nonconformities, such as late adverse event reporting, incomplete informed consent documentation, missing source data, or protocol deviations. The rigor of the CAPA lifecycle depends on accurate and timely detection, supported by robust systems for logging issues into centralized databases or electronic quality management systems (eQMS) (Roses, 2008, Selby, *et al.*, 2018, Timmermans, Venet & Burzykowski, 2016). Logging must capture not only the event itself but also contextual details such as site, study phase, investigator, and data system, which provide essential input for later root cause analysis. A systematic logging process ensures that issues are visible, traceable, and available for trend analysis, enabling organizations to identify not just isolated errors but patterns that may signal systemic weaknesses.

Containment is the next essential step, where immediate measures are taken to limit the impact of the detected issue while longer-term solutions are developed. For example, if monitoring detects that a site has not reported SAEs within the regulatory timeframe, containment may involve rapid outreach to ensure immediate reporting of pending cases. Similarly, if an audit reveals missing data, the short-term corrective action might be to initiate immediate data entry or retrieve missing records from source documents. Containment prevents further harm to patients, ensures regulatory obligations are met, and stabilizes the situation until root cause analysis can reveal more durable solutions. Without containment, issues can escalate, compromising both patient safety and data integrity before preventive measures are put in place (Smith, *et al.*, 2019, Thomford, *et al.*, 2018, Ulrich-Merzenich, *et al.*, 2009).

Root cause analysis (RCA) lies at the center of the CAPA lifecycle, as it determines whether subsequent actions will truly prevent recurrence. Several methodologies support

RCA, each offering distinct perspectives on underlying causes. The 5 Whys technique prompts investigators to repeatedly ask “why” until the deeper system-level drivers of a problem are identified. The Ishikawa, or fishbone diagram, categorizes causes into domains such as people, processes, equipment, environment, and materials, encouraging holistic analysis (Akpan, Awe & Idowu, 2019). Pareto analysis highlights the most common or impactful issues, helping organizations focus on the “vital few” that contribute most to noncompliance. For instance, if a deviation reveals repeated errors in informed consent documentation, RCA may uncover that the root cause is not staff negligence but inadequate training on updated consent templates, lack of oversight by investigators, or overly complex forms. By identifying the true root cause, organizations avoid the trap of superficial fixes and instead design corrective and preventive actions that address systemic vulnerabilities (Squires, *et al.*, 2021, Terranova, Venkatakrishnan & Benincosa, 2021).

Action planning transforms the insights of RCA into structured interventions. Corrective actions are aimed at resolving the specific incident, while preventive actions address the root cause to reduce the risk of recurrence. Corrective actions may include retraining staff involved in a deviation, correcting erroneous data entries, or updating site files. Preventive actions may involve revising SOPs, simplifying processes, introducing electronic systems to reduce manual errors, or redesigning training curricula. Effective action planning requires prioritization, balancing the urgency of corrective measures with the long-term investment in preventive strategies. Change control mechanisms must also be applied, particularly when CAPA actions involve modifications to SOPs, systems, or protocols (Boyer, *et al.*, 2018, Chin & Bairu, 2011, Diani, Rock & Moll, 2017). These changes must be documented, justified, and approved by appropriate governance structures to ensure consistency and regulatory alignment. Without structured planning and change control, corrective actions risk being piecemeal and preventive actions risk introducing unintended consequences.

Implementation is where action plans are put into practice, requiring coordination, communication, and accountability across sponsors, CROs, sites, and vendors. Implementation is not merely the execution of tasks but the orchestration of a multi-level response that may involve updating procedures, retraining staff, revising monitoring plans, and deploying new technologies. Accountability structures such as RACI matrices help clarify who is responsible, who is accountable, who must be consulted, and who must be informed. Implementation also requires adequate resourcing, including budget allocations, dedicated personnel, and technological infrastructure. A common pitfall is underestimating the effort required for preventive actions, leading to incomplete implementation and persistence of systemic weaknesses. Effective implementation therefore demands both strategic leadership and operational discipline (Giwah, *et al.*, 2020, Oluyemi, Akintimehin & Akomolafe, 2020, Petkovic, *et al.*, 2020).

Verification of effectiveness (VoE) is the critical checkpoint that determines whether CAPA has achieved its intended outcomes. VoE involves setting measurable criteria at the planning stage, such as reduced rates of specific deviations, improved timeliness of adverse event reporting, or decreased

recurrence of consent errors. These criteria are then assessed after implementation to ensure that corrective and preventive measures have truly resolved the issue and addressed the root cause. For example, if the CAPA aimed to reduce data entry delays, VoE might measure the percentage of data entered within protocol-defined timelines before and after implementation (Elebe & Imediegwu, 2020, Imediegwu & Elebe, 2020). If no improvement is observed, the CAPA may be reopened, and further root cause analysis conducted. VoE ensures that CAPA systems are not merely procedural but outcome-oriented, focused on tangible improvements in compliance, safety, and data integrity.

Closure is the formal conclusion of the CAPA lifecycle, where documentation is finalized, effectiveness verified, and lessons learned are integrated into organizational knowledge. Closure does not mean that the issue disappears from organizational memory; rather, it is archived with full traceability, ready for review by inspectors, auditors, or quality councils. Closure also provides an opportunity to disseminate lessons learned across studies and sites, ensuring that the preventive dimension of CAPA extends beyond a single incident. Mature organizations maintain CAPA libraries or lessons-learned databases that allow patterns to be analyzed and best practices to be shared. Closure thus marks not an end but the transformation of individual findings into systemic resilience.

The CAPA lifecycle functions most effectively when it is embedded within a culture of transparency, accountability, and continuous improvement. Staff must feel empowered to report deviations without fear of reprisal, confident that issues will be addressed constructively. Leadership must support CAPA with resources and governance, ensuring that preventive actions receive the same priority as corrective measures. Technology must support CAPA through integrated eQMS platforms, centralized monitoring dashboards, and automated alerts. Regulators increasingly expect evidence that CAPA systems are functioning effectively, with documented examples of detection, containment, RCA, action planning, implementation, verification, and closure. By mastering this lifecycle, organizations demonstrate not only compliance but also maturity, resilience, and commitment to patient safety and data integrity (Essien, *et al.*, 2020, Kingsley, Akomolafe & Akintimehin, 2020, Ponka, *et al.*, 2020).

In sum, the CAPA lifecycle and process design provide a structured pathway for achieving sustainable compliance in clinical trials. Detection and logging ensure visibility of issues. Containment stabilizes immediate risks. Root cause analysis uncovers systemic drivers of nonconformities. Action planning designs both corrective and preventive solutions, with change control ensuring consistency. Implementation brings these plans to life, while verification of effectiveness confirms their impact. Closure finalizes the process and integrates lessons learned into organizational knowledge. Together, these stages create a continuous improvement loop that transforms compliance from a reactive obligation into a proactive capability. When embedded into organizational culture and supported by robust systems, the CAPA lifecycle ensures that clinical trials remain credible, ethical, and resilient in an increasingly complex global landscape (Higa, *et al.*, 2020, Kent, *et al.*, 2020, Mugo, *et al.*, 2020).

#### 2.4. Digital Enablement & Data Architecture

Digital enablement and data architecture are central to the effective implementation of corrective and preventive action (CAPA) strategies in clinical trials. As trials have become larger, more decentralized, and increasingly reliant on digital systems, manual or paper-based CAPA frameworks no longer provide the responsiveness, traceability, and scalability required for sustainable compliance. Instead, organizations must leverage integrated digital platforms, advanced analytics, and harmonized data standards to transform CAPA into a proactive, data-driven function that enhances both compliance and operational efficiency. The design of this digital ecosystem rests on three pillars: the use of electronic quality management systems and issue-management tools, the integration of core clinical trial platforms with robust audit trails, and the deployment of analytics and automation capabilities that enable early risk detection, effective oversight, and sustainable improvement (Giwah, *et al.*, 2021, Oluyemi, Akintimehin & Akomolafe, 2021).

Electronic quality management systems (eQMS) and issue-management platforms provide the structural backbone of digital CAPA processes. These systems serve as centralized repositories where deviations, audit findings, inspection observations, and safety signals are logged, tracked, and resolved. By digitizing CAPA workflows, organizations gain transparency across sponsors, contract research organizations (CROs), and investigative sites, ensuring that no issue falls through the cracks. Each CAPA can be assigned to responsible personnel, tracked against timelines, and documented with evidence of implementation and verification of effectiveness. This creates a robust audit trail that satisfies regulatory expectations and supports inspection readiness. More importantly, eQMS platforms often include configurable workflows that guide users through the CAPA lifecycle from detection and containment to root cause analysis, action planning, implementation, and closure standardizing practices across global teams and reducing variability (Timmis, 2021, Wilkins, *et al.*, 2021). Issue-management tools also enable linkage between CAPA and related quality processes such as change control, training management, and vendor oversight, ensuring that corrective and preventive actions are not isolated events but integrated into the wider quality management system.

The integration of clinical trial management systems (CTMS), electronic data capture (EDC), electronic patient-reported outcomes (ePRO), and electronic source (eSource) systems with CAPA frameworks is equally essential. These platforms generate the operational and clinical data from which deviations and risks are detected. When seamlessly integrated with eQMS or issue-management systems, they provide automated triggers for CAPA initiation. For example, if EDC identifies repeated late data entries at a particular site, the issue can automatically populate in the CAPA system for investigation and action. Similarly, ePRO platforms may highlight compliance issues in patient-reported visit logs, while eSource data can reveal anomalies in laboratory values that warrant CAPA intervention (Atobatele, Hungbo & Adeyemi, 2019, Olaniyan, Uwaifo & Ojediran, 2019). CTMS systems track site performance and monitoring findings, which, when integrated with CAPA workflows, create a continuous feedback loop between trial execution and quality oversight. Audit trails embedded within these systems ensure that all changes are attributable, legible, contemporaneous,

original, and accurate, fully aligned with ALCOA+ principles and regulatory requirements under FDA 21 CFR Part 11 and EMA/MHRA guidance. This integration not only enhances traceability but also reduces manual errors and delays, ensuring that CAPA responses are both timely and data-driven.

Analytics and automation capabilities elevate CAPA beyond compliance to continuous quality improvement. Dashboards provide real-time visualization of key metrics such as deviation rates, protocol violations, adverse event reporting timelines, and CAPA cycle times. By consolidating data from multiple systems, dashboards allow sponsors and CROs to monitor compliance performance across global sites, identifying outliers and emerging risks. Automated anomaly detection algorithms can flag unusual patterns in safety data, recruitment rates, or data quality indicators, prompting CAPA initiation before issues escalate. For example, natural language processing (NLP) can be applied to free-text audit observations or monitoring reports to identify recurring themes such as informed consent errors or inadequate documentation, transforming unstructured data into actionable insights (Alsulami & Sherwood, 2020, Goodlett, *et al.*, 2020, Uwaifo & John-Ohimai, 2020). Machine learning (ML) models can predict which sites are most likely to experience future deviations based on historical patterns, enabling preventive CAPA actions such as targeted training or increased monitoring. Automation also supports CAPA workflow efficiency by generating reminders, escalating overdue actions, and linking corrective measures directly to preventive strategies, ensuring that organizational learning is embedded across the portfolio.

Standards and interoperability frameworks such as the Clinical Data Interchange Standards Consortium (CDISC) further strengthen the digital architecture of CAPA systems. By ensuring that clinical and operational data adhere to common formats such as Study Data Tabulation Model (SDTM) and Analysis Data Model (ADaM), organizations facilitate seamless integration of diverse data sources into CAPA analytics. This harmonization reduces the risk of misinterpretation, improves comparability across trials, and enhances the ability to identify systemic issues that span therapeutic areas and geographies (Awe, 2021, Bankole, Nwokediegwu & Okiye, 2021). Similarly, linking CAPA systems to the electronic Trial Master File (eTMF) ensures that all CAPA documentation including root cause analyses, action plans, implementation evidence, and verification of effectiveness reports is stored in a compliant and inspection-ready format. The eTMF linkage closes the loop between CAPA execution and regulatory submission, ensuring that corrective and preventive actions are visible, traceable, and verifiable during audits and inspections.

The impact of digital enablement and data architecture on CAPA effectiveness can be illustrated through practical examples. In oncology trials, where protocol complexity and high patient safety risks make compliance particularly challenging, centralized dashboards linked to CTMS and eQMS can flag sites with high deviation rates, enabling sponsors to initiate targeted CAPA interventions such as refresher training or protocol amendments. In rare disease studies with small patient populations, predictive analytics applied to EDC and ePRO data can highlight early signals of noncompliance, prompting preventive CAPA measures that preserve data integrity despite limited sample sizes (Imediegwu & Elebe, 2020). In decentralized or hybrid trials,

where remote monitoring replaces many on-site visits, automated anomaly detection ensures that CAPA remains responsive and effective despite the lack of physical oversight. In each case, digital systems transform CAPA from a retrospective process into a forward-looking mechanism that drives resilience and sustainability.

Ultimately, the integration of eQMS platforms, clinical trial systems, advanced analytics, interoperability standards, and eTMF linkage creates a digital ecosystem that supports sustainable clinical trial compliance. This ecosystem enables early detection of deviations, rapid initiation of CAPA workflows, data-driven root cause analysis, and systematic verification of effectiveness. It also ensures that CAPA is embedded into organizational memory through traceable documentation and cross-trial learning (Elebe & Imediegwu, 2021, Imediegwu & Elebe, 2021). By leveraging digital enablement and robust data architecture, organizations not only meet regulatory expectations but also achieve greater efficiency, reduce operational risk, and strengthen public trust in clinical research. In an environment where trials are increasingly global, complex, and technology-dependent, such digital integration is no longer optional but essential for ensuring that corrective and preventive actions deliver their intended impact protecting patients, safeguarding data integrity, and sustaining compliance across the clinical trial enterprise.

### 2.5. Governance, Roles & Vendor Oversight

Governance, roles, and vendor oversight represent the human and organizational framework within which corrective and preventive action (CAPA) strategies function. Without clear allocation of responsibilities, structured decision-making bodies, and robust oversight of vendors, CAPA risks becoming fragmented, inconsistent, or purely reactive. By defining responsibilities across sponsors, contract research organizations (CROs), sites, and vendors, establishing quality councils or CAPA boards, and applying systematic vendor qualification and auditing processes, organizations create the scaffolding for CAPA systems that are both effective and sustainable in ensuring clinical trial compliance.

The distribution of responsibilities in a CAPA system is often captured in a RACI matrix defining who is Responsible, who is Accountable, who must be Consulted, and who must be Informed. Within the context of clinical trials, sponsors typically hold accountability for overall trial quality and compliance. CROs may be delegated responsibility for day-to-day monitoring, issue detection, and CAPA execution. Sites are directly responsible for accurate conduct of the protocol, documentation, and reporting, while vendors provide services ranging from data management platforms to laboratory analysis. The clarity of this division is vital. For instance, if a protocol deviation arises from late safety reporting, the site may be responsible for timely reporting, the CRO responsible for monitoring and detection, and the sponsor accountable for ensuring that corrective and preventive actions address systemic weaknesses. By mapping CAPA activities into a RACI framework, duplication of effort and gaps in accountability are reduced, communication is streamlined, and escalation pathways become predictable (Bowman, 2013, Chang, *et al.*, 2005, Efferth, *et al.*, 2017).

CAPA boards or quality councils formalize decision-making and oversight. These cross-functional groups review CAPA logs, approve root cause analyses, and validate corrective and

preventive action plans. Their composition typically includes quality assurance, clinical operations, pharmacovigilance, regulatory affairs, and sometimes site representatives. By centralizing oversight, CAPA boards ensure consistency in how issues are classified, investigated, and resolved. They also establish thresholds for escalation, determining which issues can be managed at the site level and which require organization-wide interventions. A CAPA board reviewing recurring informed consent documentation errors might determine that retraining is not enough and escalate to a preventive action that involves redesigning consent templates or revising global SOPs. In this way, quality councils provide the governance layer that transforms CAPA from scattered local fixes into coordinated systemic improvement.

Vendor oversight is a critical dimension of CAPA governance, as many compliance risks emerge at the interface between sponsors, CROs, and third-party providers. Vendor qualification is the first line of defense, requiring assessment of a vendor's capabilities, systems, and compliance history before engagement. Qualification often involves questionnaires, audits, and reviews of certifications or prior inspection outcomes. Once engaged, vendors are bound by Quality Technical Agreements (QTAs), which specify responsibilities, data ownership, escalation processes, and CAPA expectations. For example, a QTA with a central laboratory may stipulate that deviations in data reporting timelines must be logged in the sponsor's CAPA system within a defined period, with corrective actions agreed jointly. Regular audits provide verification that vendors are fulfilling their obligations. Findings from these audits often generate CAPA, which must then be tracked to closure under the same governance structures applied to internal operations (Will, *et al.*, 2016, Zineh & Woodcock, 2013).

Competency-based training is a foundational element in sustaining CAPA effectiveness across all parties. CAPA often fails not because of weak detection or poor planning but because the individuals responsible for implementing corrective and preventive actions lack the knowledge or skills to do so effectively. Competency-based training frameworks ensure that roles are clearly defined, that staff are trained on both technical and regulatory aspects of their tasks, and that training is documented and retrievable (Bowman, 2013, Chang, *et al.*, 2005, Efferth, *et al.*, 2017). Training records serve as evidence of compliance during audits and inspections but also function as preventive tools by ensuring that staff remain current with evolving protocols, regulations, and organizational procedures. For example, if root cause analysis identifies inadequate knowledge of updated informed consent requirements as a driver of deviations, preventive actions may include rolling out updated training modules and ensuring that completion records are integrated into the eQMS. Competency-based training is not a one-off exercise but a continuous cycle aligned with CAPA outcomes, creating a feedback loop between detected issues and enhanced workforce capability.

The integration of governance, roles, and vendor oversight into CAPA design creates resilience across the clinical trial enterprise. Governance ensures that CAPA decisions are consistent and aligned with organizational priorities. Clear roles, supported by RACI frameworks, reduce ambiguity and foster accountability. Vendor oversight ensures that external partners adhere to the same standards of compliance and improvement as internal teams. Competency-based training ensures that individuals at every level are equipped to carry

out their responsibilities effectively. Together, these elements form the organizational backbone that supports sustainable compliance in complex, multi-site trials (Bowman, 2013, Chang, *et al.*, 2005, Efferth, *et al.*, 2017).

In practice, this framework can be illustrated with scenarios. Consider a deviation detected during centralized monitoring that indicates delays in adverse event reporting at multiple sites. Detection triggers immediate logging in the eQMS. Containment actions involve notifying the affected sites to expedite pending reports. Root cause analysis identifies that the delay is linked to a vendor-provided safety database interface that is not user-friendly. The CAPA board reviews the findings and approves corrective actions (enhanced training for current users) and preventive actions (vendor system redesign and updated SOPs for data entry). The QTA with the vendor is updated to include stricter performance metrics, and a follow-up audit is scheduled. Training records are reviewed to ensure all site staff are requalified on the updated processes. Closure of the CAPA is only approved after verification that reporting timeliness has improved. This example demonstrates how governance, roles, and vendor oversight interlock to transform detection into sustainable compliance.

Ultimately, sustainable clinical trial compliance is not achieved through technology or procedures alone but through the human and organizational structures that guide them. CAPA strategies succeed when governance structures ensure consistency, roles are clearly defined and supported, vendors are rigorously managed, and competencies are continuously built. These elements together create a culture of accountability, transparency, and continuous learning, where issues are not hidden but surfaced, not patched but solved, and not forgotten but transformed into organizational knowledge. By embedding governance, roles, and vendor oversight into CAPA design, sponsors and their partners build systems that are capable not only of correcting deviations but of preventing them, ensuring that clinical trials remain credible, ethical, and compliant in an increasingly demanding global environment.

## 2.6. Metrics & Performance Management

Metrics and performance management are the instruments that transform corrective and preventive action (CAPA) from a procedural requirement into a system of measurable improvement for clinical trial compliance. Without clear metrics, organizations risk implementing CAPA actions that appear corrective on paper but fail to address systemic weaknesses in practice. By defining leading and lagging indicators, establishing thresholds and alert rules, and adhering to a disciplined review cadence, organizations ensure that CAPA is not only responsive but predictive, thereby reinforcing sustainable compliance in increasingly complex multi-site trials.

Leading indicators provide early warning signals of potential issues, while lagging indicators measure outcomes after events have occurred. Both are essential. Leading indicators might include the timeliness of data entry, the frequency of minor protocol deviations, or trends in query resolution times. These measures give visibility into risks before they escalate into significant nonconformities. Lagging indicators, by contrast, capture results such as the rate of recurrence of deviations, the number of inspection findings, or the overall CAPA cycle time. Together, these indicators create a balanced scorecard of CAPA performance (Elebe &

Imdiegwu, 2021, Hassan, *et al.*, 2021). For example, monitoring leading indicators such as delayed eCRF data entry can help prevent lagging outcomes like data quality deficiencies flagged during regulatory inspections. This dual approach ensures that CAPA functions not only as a tool for correction but also as an enabler of prevention.

Thresholds and alert rules operationalize the use of metrics by defining when an indicator signals unacceptable risk. For instance, a threshold may be established that no more than 5% of informed consent forms can contain documentation errors, or that serious adverse events (SAEs) must be reported within 24 hours in 100% of cases. If these thresholds are exceeded, automated alerts can escalate issues to quality councils or CAPA boards. The discipline of threshold-setting also ensures proportionality: minor deviations trigger local corrective actions, while systemic breaches prompt organization-wide interventions. By codifying thresholds into digital systems, organizations reduce subjectivity and ensure consistent escalation pathways, improving both responsiveness and accountability.

Review cadence is equally important. CAPA systems function best when metrics are not reviewed sporadically but at predefined intervals aligned with trial risk. Monthly reviews may focus on leading indicators such as query turnaround times or protocol deviation rates, while quarterly reviews assess lagging indicators such as CAPA closure times and recurrence rates. Annual reviews may aggregate findings across portfolios, providing insight into systemic vulnerabilities such as training gaps, vendor underperformance, or recurring safety reporting delays. A structured cadence creates predictability, ensuring that CAPA oversight is proactive rather than reactive. It also fosters a culture of continuous improvement by embedding CAPA discussions into routine governance cycles (Bowman, 2013, Chang, *et al.*, 2005, Efferth, *et al.*, 2017).

Concrete examples illustrate how metrics guide CAPA performance. Deviation and recurrence rates are among the most critical indicators. High rates of protocol deviations indicate immediate compliance risk, while recurrence of the same type of deviation signals that preventive actions have failed. Monitoring both metrics ensures that CAPA strategies evolve from treating symptoms to addressing root causes. For example, if repeated deviations occur in the timing of laboratory assessments, it may not be enough to retrain site staff. The recurrence rate would prompt investigation into whether the protocol schedule itself is impractical, leading to preventive measures such as protocol amendment or patient scheduling tools (Will, *et al.*, 2016, Zineh & Woodcock, 2013).

Adverse event (AE) and serious adverse event (SAE) reporting cycle time is another vital measure, as delays directly impact patient safety and regulatory compliance. CAPA actions aimed at improving reporting timeliness can be evaluated by tracking the percentage of events reported within regulatory deadlines. Sustained improvement in cycle times following CAPA implementation provides tangible evidence of effectiveness. Conversely, persistent delays despite corrective actions may indicate deeper systemic issues such as inadequate vendor systems or unclear responsibilities between site and sponsor staff.

CAPA cycle time—the time from issue detection to CAPA closure—is a measure of efficiency. Long cycle times may indicate bottlenecks in root cause analysis, resource constraints, or lack of accountability. Monitoring cycle time

ensures that CAPA processes remain responsive and that issues are not left unresolved, exposing trials to ongoing risk. Cycle time metrics can also be stratified by issue severity, with critical issues expected to close more rapidly than minor deviations. By benchmarking cycle times across studies, organizations can identify best practices and standardize efficient workflows (Bowman, 2013, Chang, *et al.*, 2005, Efferth, *et al.*, 2017).

Verification of effectiveness (VoE) pass rate is another key metric, indicating the proportion of CAPA actions that achieve their intended outcomes. A low VoE pass rate suggests that actions are superficial or that root causes are poorly understood. Improving this rate requires more rigorous root cause analysis and better alignment of preventive actions with systemic vulnerabilities. High VoE pass rates demonstrate maturity in CAPA systems, where organizations consistently design and implement interventions that deliver lasting improvements (Awe & Akpan, 2017, Imediogwu & Elebe, 2020).

Query rates and query turnaround times provide operational insight into data quality. High query rates may indicate inadequate site training or overly complex case report forms. Long turnaround times suggest poor responsiveness or lack of resources at sites. Both measures can trigger CAPA, with corrective actions focusing on immediate query resolution and preventive actions targeting training, system redesign, or monitoring strategies. By linking query metrics to CAPA workflows, organizations ensure that data quality issues are not only resolved but prevented from recurring.

Site risk tiering is another powerful tool, classifying sites based on risk indicators such as deviation rates, data entry timeliness, audit findings, and staff turnover. High-risk sites can then be prioritized for CAPA interventions such as targeted training, increased monitoring, or additional oversight. Low-risk sites may receive more flexibility, promoting efficient resource allocation. Tiering also supports portfolio-level CAPA strategies, ensuring that preventive actions are tailored to site-specific risks while maintaining overall consistency in compliance standards (Will, *et al.*, 2016, Zineh & Woodcock, 2013).

Metrics and performance management also foster regulatory confidence. Inspectors increasingly expect sponsors and CROs to demonstrate not only that CAPA systems exist but that they are monitored for effectiveness using defined indicators. Being able to present dashboards showing declining recurrence rates, improved SAE reporting times, reduced CAPA cycle times, and high VoE pass rates provides compelling evidence of sustainable compliance. It also signals that the organization has moved beyond reactive problem-solving to proactive risk management.

The cultural impact of metrics should not be underestimated. Transparent reporting of CAPA performance fosters accountability and encourages teams to view compliance not as an abstract requirement but as a measurable, improvable outcome. When staff see that deviations are tracked, analyzed, and resolved systematically, and that preventive actions lead to real performance improvements, confidence in the CAPA process grows. Equally, when vendors are held accountable through metrics tied to QTAs and audits, external partners become integrated into the compliance culture (Bowman, 2013, Chang, *et al.*, 2005, Efferth, *et al.*, 2017).

In conclusion, metrics and performance management transform CAPA from a checklist activity into a dynamic

system of continuous improvement. Leading indicators provide early warnings, lagging indicators measure outcomes, thresholds and alert rules ensure proportional responses, and structured review cadence embeds CAPA into organizational routines. Metrics such as deviation and recurrence rates, AE/SAE reporting cycle times, CAPA cycle times, VoE pass rates, query rates, and site risk tiering provide concrete measures of performance, guiding both corrective and preventive actions. By systematically applying these measures, organizations not only ensure compliance but also build resilient systems that protect patients, safeguard data integrity, and reinforce trust in clinical research. Sustainable compliance is achieved not through isolated fixes but through the disciplined use of metrics that turn CAPA into a measurable, accountable, and continuously improving capability.

## 2.7. Implementation Roadmap, Pitfalls & Continuous Improvement

Implementation of corrective and preventive action (CAPA) strategies in clinical trials is most effective when supported by a roadmap that guides organizations from initial maturity assessment through continuous improvement. Sustainable compliance does not emerge spontaneously; it is the product of careful planning, phased execution, vigilant monitoring, and adaptation in the face of common pitfalls. Equally, the roadmap must reflect ethical obligations to patients, regulatory expectations regarding data privacy and safety, and the broader commitment to sustainability in clinical research.

The journey begins with maturity assessment, a structured appraisal of an organization's existing CAPA processes and quality management culture. At this stage, leadership examines whether systems for issue detection, root cause analysis, corrective planning, and preventive action are consistently applied across studies and geographies. Some organizations may find that CAPA is handled in a fragmented or reactive manner, with issues logged but not systematically trended, root causes identified only superficially, or preventive actions underdeveloped. Maturity models help benchmark these capabilities, classifying organizations as early-stage, developing, or advanced. For instance, a sponsor relying on paper-based logs and ad hoc follow-up would be considered low maturity, while one that operates a centralized electronic CAPA system with global oversight councils and predictive analytics would be at the higher end (Bowman, 2013, Chang, *et al.*, 2005, Efferth, *et al.*, 2017).

Gap analysis follows naturally from maturity assessment, highlighting the distance between current capabilities and desired compliance outcomes. Typical gaps include insufficient root cause analysis training, absence of verification of effectiveness procedures, fragmented vendor oversight, or weak integration of CAPA with other quality processes such as risk-based monitoring (Will, *et al.*, 2016, Zineh & Woodcock, 2013). By identifying these gaps, organizations create a prioritized roadmap. Some gaps may be addressed through quick wins such as standardized CAPA templates or training refreshers, while others require more strategic investment in digital systems or organizational culture change. Gap analysis is not static; it must be revisited periodically to ensure alignment with evolving regulations, technologies, and trial designs.

Pilots represent the bridge between analysis and full-scale deployment. Rather than attempting to overhaul CAPA

processes across an entire global portfolio at once, organizations select one or two high-risk or high-visibility trials to test enhanced CAPA frameworks. Pilots allow for experimentation with new technologies, workflows, or governance structures in a controlled environment. For example, a pilot might involve implementing a new electronic quality management system for CAPA tracking in a rare-disease trial with a small but geographically dispersed site network. Lessons learned regarding usability, data integration, and staff adoption can then inform broader rollout. Pilots also generate early evidence of impact, such as reduced CAPA cycle times or improved verification of effectiveness rates, which can be used to build organizational buy-in for wider implementation.

Scaling up requires structured planning and change management. Expansion of CAPA enhancements across multiple studies, CROs, and vendors involves more than replicating pilot practices; it requires tailoring solutions to diverse geographies, therapeutic areas, and operational contexts. Change management ensures that staff understand not only the mechanics of new processes but also their value. This involves leadership communication, stakeholder engagement, incentives for adoption, and ongoing training. Resistance to change is common, particularly where CAPA has historically been viewed as punitive or bureaucratic. A well-executed change management plan reframes CAPA as a tool for improvement, resilience, and patient safety rather than blame assignment. Without such cultural shifts, even the most sophisticated CAPA systems risk superficial compliance and poor sustainability (Will, *et al.*, 2016, Zineh & Woodcock, 2013).

Common pitfalls can undermine CAPA effectiveness if not proactively addressed. One frequent failure is reliance on symptom fixes rather than addressing root causes. For instance, retraining staff after a deviation may correct behavior temporarily but will not resolve systemic issues such as unrealistic protocol requirements or poorly designed data entry systems. Weak verification of effectiveness (VoE) is another pitfall, where CAPA is closed without rigorous assessment of whether recurrence has been prevented. A third common barrier is organizational culture, where staff fear reporting issues, quality teams operate in silos, or leadership prioritizes speed over compliance. These pitfalls can be mitigated by strengthening RCA training, embedding VoE criteria into CAPA workflows, and cultivating a culture of transparency and learning.

Continuous improvement requires organizations to move beyond one-time fixes toward dynamic learning systems. CAPA outcomes must be trended over time to identify systemic vulnerabilities, such as recurring informed consent documentation errors or repeated delays in SAE reporting across multiple trials. Lessons learned must be shared across studies, functions, and geographies, transforming isolated CAPA events into portfolio-wide preventive strategies. Continuous improvement also demands investment in digital tools that enable predictive analytics, anomaly detection, and real-time dashboards, shifting CAPA from reactive remediation to proactive prevention (Awe & Akpan, 2017, Imediegwu & Elebe, 2020).

The roadmap must also honor ethical and regulatory obligations. Patient safety is the ultimate objective of CAPA, requiring that corrective actions address risks to participants promptly and preventive measures reduce future harms. Data privacy regulations such as HIPAA in the United States and

GDPR in Europe mandate that CAPA systems preserve confidentiality while enabling traceability. Sustainability considerations remind organizations that CAPA is not simply about avoiding inspection findings but about embedding resilience and integrity into the clinical trial enterprise. By aligning CAPA with broader commitments to transparency, accountability, and equity, organizations ensure that compliance is meaningful and enduring.

Case snapshots illustrate how these principles play out in practice. In one oncology trial, maturity assessment revealed fragmented CAPA tracking across sites. A pilot implementation of an eQMS created centralized visibility of deviations and CAPA actions. Gap analysis highlighted weaknesses in root cause analysis, leading to targeted training for investigators. Scale-up across other oncology studies resulted in measurable improvements, including a 30% reduction in recurrence of protocol deviations. In another example, a rare-disease trial experienced repeated delays in SAE reporting. RCA revealed that the root cause was not site negligence but a confusing interface in the vendor's safety database. Corrective actions included expedited reporting of pending cases, while preventive measures involved redesign of the interface and updates to the quality technical agreement with the vendor. Verification of effectiveness demonstrated sustained improvement in reporting cycle times, reinforcing the value of addressing systemic causes rather than symptoms.

In conclusion, the implementation roadmap for CAPA in clinical trials requires a phased approach beginning with maturity assessment and gap analysis, advancing through pilots, and scaling up with disciplined change management. Common pitfalls such as symptom-focused fixes, weak verification of effectiveness, and cultural barriers must be proactively mitigated. Continuous improvement, rooted in trending, sharing lessons learned, and leveraging digital tools, ensures that CAPA evolves into a preventive capability rather than a reactive obligation. Ethical imperatives of patient safety, data privacy, and sustainability remain central, reminding organizations that CAPA is not simply about satisfying regulators but about safeguarding participants and strengthening trust in clinical research. By following this roadmap and addressing its pitfalls with transparency and rigor, clinical trial organizations can achieve sustainable compliance in an increasingly complex and global research environment (Will, *et al.*, 2016, Zineh & Woodcock, 2013).

### 3. Conclusion

Implementing corrective and preventive action as a sustained capability not a one-off fix reframes compliance as a strategic advantage in modern, multi-site clinical research. Grounded in the expectations of ICH E6(R3)/E8(R1) and major regulators, aligned with ALCOA+ data principles, and operationalized through a disciplined lifecycle of detection, containment, root cause analysis, action planning, implementation, verification of effectiveness, and closure, CAPA becomes the engine of continuous learning. When embedded within a risk-based quality management approach, the focus shifts from reacting to isolated defects to anticipating and preventing system-level failures that jeopardize patient safety and data credibility.

Sustainable results depend on the fusion of people, process, and technology. eQMS-driven workflows integrated with CTMS/EDC/ePRO/eSource systems, audit trails, CDISC-conformant datasets, analytics dashboards, and eTMF

linkage provide traceability and speed from signal to solution. Governance structures RACI clarity across sponsors, CROs, sites, and vendors; active CAPA boards; rigorous vendor qualification and QTAs; and competency-based training with defensible records create accountability and resilience at scale. Metrics close the loop: leading and lagging indicators, risk-proportional thresholds, and a disciplined review cadence translate intent into measurable performance, using deviation and recurrence rates, AE/SAE reporting cycle time, CAPA cycle time, VoE pass rate, query rate, and site risk tiering to guide decisions.

Execution must be phased and adaptive. Maturity assessment and gap analysis enable targeted pilots; structured scale-up with change management embeds new behaviors; and explicit mitigations for common pitfalls symptom-level fixes, weak VoE, and cultural resistance preserve momentum. Throughout, ethics, patient safety, and privacy (HIPAA/GDPR) remain non-negotiable guardrails, while a sustainability mindset ensures that improvements endure despite staff turnover, protocol amendments, and geographic expansion.

The destination is a proactive, data-driven, and human-centered quality system where CAPA and RBQM work in concert, digital enablement accelerates insight-to-action, and governance sustains accountability. Organizations that institutionalize this model protect participants, strengthen scientific validity, withstand regulatory scrutiny, and earn public trust delivering clinical trials that are not only compliant today but reliably compliant tomorrow.

#### 4. References

- Adeyemi C, Ajayi OO, Sagay I, Oparah S. A strategic workforce model for expanding nurse-led primary care in underserved communities. [place unknown: publisher unknown]; 2021.
- Adeyemi C, Ajayi OO, Sagay I, Oparah S. Integrating social determinants of health into nursing practice: a framework-based review. [place unknown: publisher unknown]; 2021.
- Adeyemo KS, Mbata AO, Balogun OD. The role of cold chain logistics in vaccine distribution: addressing equity and access challenges in Sub-Saharan Africa. [place unknown: publisher unknown]; 2021.
- Agrafiotis DK, Lobanov VS, Farnum MA, Yang E, Ciervo J, Walega M, *et al.* Risk-based monitoring of clinical trials: an integrative approach. *Clin Ther.* 2018;40(7):1204-12.
- Ajayi SAO, Akanji OO. Impact of BMI and menstrual cycle phases on salivary amylase: a physiological and biochemical perspective. [place unknown: publisher unknown]; 2021.
- Akpan UU, Adekoya KO, Awe ET, Garba N, Oguncocker GD, Ojo SG. Mini-STRs screening of 12 relatives of Hausa origin in northern Nigeria. *Niger J Basic Appl Sci.* 2017;25(1):48-57.
- Akpan UU, Awe TE, Idowu D. Types and frequency of fingerprint minutiae in individuals of Igbo and Yoruba ethnic groups of Nigeria. *Ruhuna J Sci.* 2019;10(1).
- Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries-a systematic review. *Int J Equity Health.* 2018;17(1):37.
- Alsulami SA, Sherwood G. The experience of culturally diverse faculty in academic environments: a multi-country scoping review. *Nurse Educ Pract.* 2020;44:102777.
- Armstrong AW, Watson AJ, Makredes M, Frangos JE, Kimball AB, Kvedar JC. Text-message reminders to improve sunscreen use: a randomized, controlled trial using electronic monitoring. *Arch Dermatol.* 2009;145(11):1230-6.
- Arora N, Maurya PK, Kacker P. Translational research in drug discovery and development. In: *Translational bioinformatics and its application.* Dordrecht: Springer Netherlands; 2017. p. 55-87.
- Atobatele OK, Hungbo AQ, Adeyemi C. Digital health technologies and real-time surveillance systems: transforming public health emergency preparedness through data-driven decision making. [place unknown: publisher unknown]; 2019.
- Atobatele OK, Hungbo AQ, Adeyemi C. Evaluating the strategic role of economic research in supporting financial policy decisions and market performance metrics. [place unknown: publisher unknown]; 2019.
- Atobatele OK, Hungbo AQ, Adeyemi C. Leveraging big data analytics for population health management: a comparative analysis of predictive modeling approaches in chronic disease prevention and healthcare resource optimization. [place unknown: publisher unknown]; 2019.
- Awe ET. Hybridization of snout mouth deformed and normal mouth African catfish *Clarias gariepinus*. *Anim Res Int.* 2017;14(3):2804-8.
- Awe ET, Akpan UU. Cytological study of *Allium cepa* and *Allium sativum*. [place unknown: publisher unknown]; 2017.
- Awe ET, Akpan UU, Adekoya KO. Evaluation of two MiniSTR loci mutation events in five Father-Mother-Child trios of Yoruba origin. *Niger J Biotechnol.* 2017;33:120-4.
- Awe T. Cellular localization of iron-handling proteins required for magnetic orientation in *C. elegans*. [place unknown: publisher unknown]; 2021.
- Bankole AO, Nwokediegwu ZS, Okiye SE. Emerging cementitious composites for 3D printed interiors and exteriors: a materials innovation review. *J Front Multidiscip Res.* 2020;1(1):127-44.
- Bankole AO, Nwokediegwu ZS, Okiye SE. A conceptual framework for AI-enhanced 3D printing in architectural component design. *J Front Multidiscip Res.* 2021;2(2):103-19.
- Barger S, Sullivan SD, Bell-Brown A, Bott B, Ciccarella AM, Golenski J, *et al.* Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care. *BMC Med Res Methodol.* 2019;19(1):119.
- Barnes B, Stansbury N, Brown D, Garson L, Gerard G, Piccoli N, *et al.* Risk-based monitoring in clinical trials: past, present, and future. *Ther Innov Regul Sci.* 2021;55(4):899-906.
- Beck D, Asghar A, Kenworthy-Heinige T, Johnson MR, Willis C, Kantorowicz AS, *et al.* Increasing access to clinical research using an innovative mobile recruitment approach: the (MoRe) concept. *Contemp Clin Trials Commun.* 2020;19:100623.
- Bhatt A. Quality of clinical trials: a moving target. *Perspect Clin Res.* 2011;2(4):124-8.
- Bowman S. Impact of electronic health record systems on information integrity: quality and safety implications.

- Perspect Health Inf Manag. 2013;10(Fall):1c.
26. Boyer AP, Fair AM, Joosten YA, Dolor RJ, Williams NA, Sherden L, *et al.* A multilevel approach to stakeholder engagement in the formulation of a clinical data research network. *Med Care.* 2018;56:S22-S26.
  27. Burgess HE, Chataway J. The importance of mentorship and collaboration for scientific capacity-building and capacity-sharing: perspectives of African scientists. *F1000Res.* 2021;10.
  28. Chang A, Schyve PM, Croteau RJ, O'Leary DS, Loeb JM. The JCAHO patient safety event taxonomy: a standardized terminology and classification schema for near misses and adverse events. *Int J Qual Health Care.* 2005;17(2):95-105.
  29. Chianumba EC, Ikhalea NURA, Mustapha AY, Forkuo AY, Osamika DAMILOLA. A conceptual framework for leveraging big data and AI in enhancing healthcare delivery and public health policy. *IRE J.* 2021;5(6):303-10.
  30. Chin R, Bairu M, editors. *Global clinical trials: effective implementation and management.* San Diego: Academic Press; 2011.
  31. Cruz Rivera S, Torlinska B, Marston E, Denniston AK, Oliver K, Hoare S, *et al.* Advancing UK regulatory science strategy in the context of global regulation: a stakeholder survey. *Ther Innov Regul Sci.* 2021;55(4):646-55.
  32. Curtis NJ, Foster JD, Miskovic D, Brown CS, Hewett PJ, Abbott S, *et al.* Association of surgical skill assessment with clinical outcomes in cancer surgery. *JAMA Surg.* 2020;155(7):590-8.
  33. de Sá Vale AM. Risk management in clinical trials clinical research sites [master's thesis]. Lisboa: Universidade NOVA de Lisboa; 2021.
  34. Diani CA, Rock A, Moll P. An evaluation of the effectiveness of a risk-based monitoring approach implemented with clinical trials involving implantable cardiac medical devices. *Clin Trials.* 2017;14(6):575-83.
  35. Efferth T, Saeed ME, Mirghani E, Alim A, Yassin Z, Saeed E, *et al.* Integration of phytochemicals and phytotherapy into cancer precision medicine. *Oncotarget.* 2017;8(30):50284.
  36. Elebe O, Imediegwu CC. A predictive analytics framework for customer retention in African retail banking sectors. *IRE J.* 2020;3(7).
  37. Elebe O, Imediegwu CC. Data-driven budget allocation in microfinance: a decision support system for resource-constrained institutions. *IRE J.* 2020;3(12).
  38. Elebe O, Imediegwu CC. Behavioral segmentation for improved mobile banking product uptake in underserved markets. *IRE J.* 2020;3(9).
  39. Elebe O, Imediegwu CC. A business intelligence model for monitoring campaign effectiveness in digital banking. *J Front Multidiscip Res.* 2021;2(1):323-33.
  40. Elebe O, Imediegwu CC. A credit scoring system using transaction-level behavioral data for MSMEs. *J Front Multidiscip Res.* 2021;2(1):312-22.
  41. Ellenberg SS, Fleming TR, DeMets DL. *Data monitoring committees in clinical trials: a practical perspective.* Chichester: John Wiley & Sons; 2019.
  42. Eneogu RA, Mitchell EM, Ogbudebe C, Aboki D, Anyebe V, Dimkpa CB, *et al.* Operationalizing mobile computer-assisted TB screening and diagnosis with Wellness on Wheels (WoW) in Nigeria: balancing feasibility and iterative efficiency. [place unknown: publisher unknown]; 2020.
  43. Enna SJ, Williams M. Defining the role of pharmacology in the emerging world of translational research. In: *Advances in pharmacology.* Vol. 57. San Diego: Academic Press; 2009. p. 1-30.
  44. Essien IA, Cadet E, Ajayi JO, Erigha ED, Obuse E. Cyber risk mitigation and incident response model leveraging ISO 27001 and NIST for global enterprises. *IRE J.* 2020;3(7):379-88.
  45. Essien IA, Cadet E, Ajayi JO, Erigha ED, Obuse E. Integrated governance, risk, and compliance framework for multi-cloud security and global regulatory alignment. *IRE J.* 2019;3(3):215-24.
  46. Essien IA, Cadet E, Ajayi JO, Erigha ED, Obuse E. Regulatory compliance monitoring system for GDPR, HIPAA, and PCI-DSS across distributed cloud architectures. *IRE J.* 2020;3(12):409-20.
  47. Fenlon D, Chivers Seymour K, Okamoto I, Winter J, Richardson A, Addington-Hall J, *et al.* Lessons learnt recruiting to a multi-site UK cohort study to explore recovery of health and well-being after colorectal cancer (CREW study). *BMC Med Res Methodol.* 2013;13(1):153.
  48. Fneish F, Schaarschmidt F, Fortwengel G. Improving risk assessment in clinical trials: toward a systematic risk-based monitoring approach. *Curr Ther Res.* 2021;95:100643.
  49. Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. *Fundamentals of clinical trials.* New York: Springer; 2015.
  50. Giwah ML, Nwokediegwu ZS, Etukudoh EA, Gbabo EY. A resilient infrastructure financing framework for renewable energy expansion in Sub-Saharan Africa. *IRE J.* 2020;3(12):382-94.
  51. Giwah ML, Nwokediegwu ZS, Etukudoh EA, Gbabo EY. A systems thinking model for energy policy design in Sub-Saharan Africa. *IRE J.* 2020;3(7):313-24.
  52. Giwah ML, Nwokediegwu ZS, Etukudoh EA, Gbabo EY. Sustainable energy transition framework for emerging economies: policy pathways and implementation gaps. *Int J Multidiscip Evol Res.* 2020;1(1):1-6.
  53. Giwah ML, Nwokediegwu ZS, Etukudoh EA, Gbabo EY. Integrated waste-to-energy policy model for urban sustainability in West Africa. *Int J Multidiscip Futur Dev.* 2021;2(1):1-7.
  54. Giwah ML, Nwokediegwu ZS, Etukudoh EA, Gbabo EY. A strategic blueprint model for poverty and unemployment reduction through public policy interventions. *Int J Multidiscip Futur Dev.* 2021;2(2):1-6.
  55. Giwah ML, Nwokediegwu ZS, Etukudoh EA, Gbabo EY. Designing a circular economy governance framework for urban waste management in African megacities. *Int J Multidiscip Evol Res.* 2021;2(2):20-27.
  56. Gong Y, Kang H, Wu X, Hua L. Enhancing patient safety event reporting. *Appl Clin Inform.* 2017;8(3):893-909.
  57. Goodlett D, Hung A, Feriozzi A, Lu H, Bekelman JE, Mullins CD. Site engagement for multi-site clinical trials. *Contemp Clin Trials Commun.* 2020;19:100608.
  58. Hamilton AB, Yano EM. The importance of symbolic and engaged participation in evidence-based quality

- improvement in a complex integrated healthcare system: response to “The science of stakeholder engagement in research”. *Transl Behav Med.* 2017;7(3):492-4.
59. Hassan YG, Collins A, Babatunde GO, Alabi AA, Mustapha SD. AI-driven intrusion detection and threat modeling to prevent unauthorized access in smart manufacturing networks. *Artif Intell (AI).* 2021;16.
  60. Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, *et al.* Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. *JAMA Intern Med.* 2017;177(12):1808-17.
  61. Hedt-Gauthier BL, Chilengi R, Jackson E, Michel C, Napua M, Odhiambo J, *et al.* Research capacity building integrated into PHIT projects: leveraging research and research funding to build national capacity. *BMC Health Serv Res.* 2017;17(Suppl 3):825.
  62. Hendricks-Ferguson VL, Cherven BO, Burns DS, Docherty SL, Phillips-Salimi CR, Roll L, *et al.* Recruitment strategies and rates of a multi-site behavioral intervention for adolescents and young adults with cancer. *J Pediatr Health Care.* 2013;27(6):434-42.
  63. Higa A, Yagi M, Hayashi K, Kosako M, Akiho H. Risk-based monitoring approach to ensure the quality of clinical study data and enable effective monitoring. *Ther Innov Regul Sci.* 2020;54(1):139-43.
  64. Hoffmann B, Rohe J. Patient safety and error management: what causes adverse events and how can they be prevented? *Dtsch Arztebl Int.* 2010;107(6):92.
  65. Hopkins J, Burns E, Eden T. International twinning partnerships: an effective method of improving diagnosis, treatment and care for children with cancer in low-middle income countries. *J Cancer Policy.* 2013;1(1-2):e8-e19.
  66. Hungbo AQ, Adeyemi C. Laboratory safety and diagnostic reliability framework for resource-constrained blood bank operations. [place unknown: publisher unknown]; 2019.
  67. Hungbo AQ, Adeyemi C, Ajayi OO. Power BI-based clinical decision support system for evidence-based nurse decision-making. [place unknown: publisher unknown]; 2019.
  68. Hurley C, Shiely F, Power J, Clarke M, Eustace JA, Flanagan E, *et al.* Risk based monitoring (RBM) tools for clinical trials: a systematic review. *Contemp Clin Trials.* 2016;51:15-27.
  69. Imediegwu CC, Elebe O. KPI integration model for small-scale financial institutions using Microsoft Excel and Power BI. *IRE J.* 2020;4(2).
  70. Imediegwu CC, Elebe O. Optimizing CRM-based sales pipelines: a business process reengineering model. *IRE J.* 2020;4(6).
  71. Imediegwu CC, Elebe O. Leveraging process flow mapping to reduce operational redundancy in branch banking networks. *IRE J.* 2020;4(4).
  72. Imediegwu CC, Elebe O. Customer experience modeling in financial product adoption using Salesforce and Power BI. *Int J Multidiscip Res Growth Eval.* 2021;2(5):484-94.
  73. Isa AK, Johnbull OA, Oveneri AC. Evaluation of Citrus sinensis (orange) peel pectin as a binding agent in erythromycin tablet formulation. *World J Pharm Pharm Sci.* 2021;10(10):188-202.
  74. Isa A, Dem B. Integrating self-reliance education curriculum for Purdah women in Northern Nigeria: a panacea for a lasting culture of peace. [place unknown: publisher unknown]; 2014.
  75. Johnson MR, Kenworthy-Heinige T, Beck DJ, Asghar A, Broussard EB, Bratcher K, *et al.* Research site mentoring: a novel approach to improving study recruitment. *Contemp Clin Trials Commun.* 2018;9:172-7.
  76. K Gohagan J, Brien B, A Hasson M, D Umbel K, Bridgeman B, S Kramer B, *et al.* Comprehensive quality management (CQM) in the PLCO Trial. *Rev Recent Clin Trials.* 2015;10(3):223-32.
  77. Kent J, Thornton M, Fong A, Hall E, Fitzgibbons S, Sava J. Acute provider stress in high stakes medical care: implications for trauma surgeons. *J Trauma Acute Care Surg.* 2020;88(3):440-5.
  78. Kingsley O, Akomolafe OO, Akintimehin OO. A community-based health and nutrition intervention framework for crisis-affected regions. *Iconic Res Eng J.* 2020;3(8):311-33.
  79. Komi LS, Chianumba EC, Forkuo AY, Osamika D, Mustapha AY. A conceptual framework for telehealth integration in conflict zones and post-disaster public health responses. *Iconic Res Eng J.* 2021;5(6):342-59.
  80. Komi LS, Chianumba EC, Forkuo AY, Osamika D, Mustapha AY. Advances in community-led digital health strategies for expanding access in rural and underserved populations. *Iconic Res Eng J.* 2021;5(3):299-317.
  81. Komi LS, Chianumba EC, Forkuo AY, Osamika D, Mustapha AY. Advances in public health outreach through mobile clinics and faith-based community engagement in Africa. *Iconic Res Eng J.* 2021;4(8):159-78.
  82. Lewis S, Bloom J, Rice J, Naeim A, Shortell S. Using teams to implement personalized health care across a multi-site breast cancer network. In: *Population health management in health care organizations.* Bingley: Emerald Group Publishing Limited; 2014. p. 71-94.
  83. Liu Y, Nandita MD, Shankar LK, Kauczor HU, Trattinig S, Collette S, *et al.* A risk management approach for imaging biomarker-driven clinical trials in oncology. *Lancet Oncol.* 2015;16(16):e622-e628.
  84. Macefield RC, Beswick AD, Blazeby JM, Lane JA. A systematic review of on-site monitoring methods for health-care randomised controlled trials. *Clin Trials.* 2013;10(1):104-24.
  85. Marković L. Improvement of business processes in public utility companies. [place unknown: publisher unknown]; 2019.
  86. Menson WNA, Olawepo JO, Bruno T, Gbadamosi SO, Nalda NF, Anyebe V, *et al.* Reliability of self-reported mobile phone ownership in rural north-Central Nigeria: cross-sectional study. *JMIR Mhealth Uhealth.* 2018;6(3):e8760.
  87. Merotiwon DO, Akintimehin OO, Akomolafe OO. Developing an information governance integration model for clinical governance committees in Sub-Saharan health systems. [place unknown: publisher unknown]; 2021.
  88. Middleton B, Bloomrosen M, Dente MA, Hashmat B, Koppel R, Overhage JM, *et al.* Enhancing patient safety and quality of care by improving the usability of electronic health record systems: recommendations from

- AMIA. *J Am Med Inform Assoc.* 2013;20(e1):e2-e8.
89. Mugo C, Njuguna I, Nduati M, Omondi V, Otieno V, Nyapara F, *et al.* From research to international scale-up: stakeholder engagement essential in successful design, evaluation and implementation of paediatric HIV testing intervention. *Health Policy Plan.* 2020;35(9):1180-7.
  90. Nchinda TC. Research capacity strengthening in the South. *Soc Sci Med.* 2002;54(11):1699-711.
  91. Nichols JH. Laboratory quality control based on risk management. *Ann Saudi Med.* 2011;31(3):223-8.
  92. Nicholson K, Ganann R, Bookey-Bassett S, Baird LG, Garnett A, Marshall Z, *et al.* Capacity building and mentorship among pan-Canadian early career researchers in community-based primary health care. *Prim Health Care Res Dev.* 2020;21:e3.
  93. Obodozie OO. Pharmacokinetics and drug interactions of herbal medicines: a missing critical step in the phytomedicine/drug development process. In: *Reading in advanced pharmacokinetics-theory, methods, and applications.* Croatia: InTech; 2012. p. 127-56.
  94. Olaniyan MF, Ale SA, Uwaifo F. Raw cucumber (*Cucumis sativus*) fruit juice as possible first-aid antidote in drug-induced toxicity. *Recent Adv Biol Med.* 2019;5:10171.
  95. Olaniyan MF, Ojediran TB, Uwaifo F, Azeez MM. Host immune responses to mono-infections of *Plasmodium* spp., hepatitis B virus, and *Mycobacterium tuberculosis* as evidenced by blood complement 3, complement 5, tumor necrosis factor- $\alpha$  and interleukin-10. *Community Acquir Infect.* 2018;5.
  96. Olaniyan MF, Uwaifo F, Ojediran TB. Possible viral immunochemical status of children with elevated blood fibrinogen in some herbal homes and hospitals in Nigeria. *Environ Dis.* 2019;4(3):81-6.
  97. Oluyemi MD, Akintimehin OO, Akomolafe OO. Designing a cross-functional framework for compliance with health data protection laws in multijurisdictional healthcare settings. *Iconic Res Eng J.* 2020;4(4):279-96.
  98. Oluyemi MD, Akintimehin OO, Akomolafe OO. Developing a framework for data quality assurance in electronic health record (EHR) systems in healthcare institutions. *Iconic Res Eng J.* 2020;3(12):335-49.
  99. Oluyemi MD, Akintimehin OO, Akomolafe OO. Framework for leveraging health information systems in addressing substance abuse among underserved populations. *Iconic Res Eng J.* 2020;4(2):212-26.
  100. Oluyemi MD, Akintimehin OO, Akomolafe OO. Modeling health information governance practices for improved clinical decision-making in urban hospitals. *Iconic Res Eng J.* 2020;3(9):350-62.
  101. Oluyemi MD, Akintimehin OO, Akomolafe OO. A strategic framework for aligning clinical governance and health information management in multi-specialty hospitals. *J Front Multidiscip Res.* 2021;2(1):175-84.
  102. Oluyemi MD, Akintimehin OO, Akomolafe OO. Developing a risk-based surveillance model for ensuring patient record accuracy in high-volume hospitals. *J Front Multidiscip Res.* 2021;2(1):196-204.
  103. Onyeji GN, Sanusi RA. Diet quality of women of childbearing age in South-east Nigeria. *Nutr Food Sci.* 2018;48(2):348-64.
  104. Özenver N, Efferth T. Integration of phytochemicals and phytotherapy into cancer precision medicine. In: *Approaching complex diseases: network-based pharmacology and systems approach in bio-medicine.* Cham: Springer International Publishing; 2020. p. 355-92.
  105. Petkovic J, Riddle A, Akl EA, Khabsa J, Lytvyn L, Atwere P, *et al.* Protocol for the development of guidance for stakeholder engagement in health and healthcare guideline development and implementation. *Syst Rev.* 2020;9(1):21.
  106. Pillai G, Chibale K, Constable EC, Keller AN, Gutierrez MM, Mirza F, *et al.* The next generation scientist program: capacity-building for future scientific leaders in low-and middle-income countries. *BMC Med Educ.* 2018;18(1):233.
  107. Ponka D, Coffman M, Fraser-Barclay KE, Fortier RD, Howe A, Kidd M, *et al.* Fostering global primary care research: a capacity-building approach. *BMJ Glob Health.* 2020;5(7):e002470.
  108. Raj A. A review on corrective action and preventive action (CAPA). *Afr J Pharm Pharmacol.* 2016;10(1):1-6.
  109. Rosemann A. Challenges to international stem cell clinical trials in countries with diverging regulations. In: *Safety, ethics and regulations.* Cham: Springer International Publishing; 2017. p. 301-19.
  110. Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. *Nat Rev Drug Discov.* 2008;7(10):807-17.
  111. Selby JV, Grossman C, Zirkle M, Barbash S. Multistakeholder engagement in PCORnet, the national patient-centered clinical research network. *Med Care.* 2018;56:S4-S5.
  112. Shyur LF, Yang NS. Metabolomics for phytomedicine research and drug development. *Curr Opin Chem Biol.* 2008;12(1):66-71.
  113. Smith L, Tan A, Stephens JD, Hibler D, Duffy SA. Overcoming challenges in multisite trials. *Nurs Res.* 2019;68(3):227-36.
  114. Squires JE, Hutchinson AM, Coughlin M, Bashir K, Curran J, Grimshaw JM, *et al.* Stakeholder perspectives of attributes and features of context relevant to knowledge translation in health settings: a multi-country analysis. *Int J Health Policy Manag.* 2021;11(8):1373.
  115. Taiwo KA. AI in population health: scaling preventive models for age-related diseases in the United States. *Int J Sci Res Arch.* 2025;16(1):1240-60.
  116. Terranova N, Venkatakrishnan K, Benincosa LJ. Application of machine learning in translational medicine: current status and future opportunities. *AAPS J.* 2021;23(4):74.
  117. Thomford NE, Dzobo K, Chimusa E, Andrae-Marobela K, Chirikure S, Wonkam A, *et al.* Personalized herbal medicine? A roadmap for convergence of herbal and precision medicine biomarker innovations. *OMICS.* 2018;22(6):375-91.
  118. Thornicroft G, Cooper S, Bortel TV, Kakuma R, Lund C. Capacity building in global mental health research. *Harv Rev Psychiatry.* 2012;20(1):13-24.
  119. Timmermans C, Venet D, Burzykowski T. Data-driven risk identification in phase III clinical trials using central statistical monitoring. *Int J Clin Oncol.* 2016;21(1):38-45.
  120. Timmis JK. Improving healthcare innovation and decision making by extensive stakeholder involvement. [place unknown: publisher unknown]; 2021.
  121. Ulrich-Merzenich G, Panek D, Zeitler H, Wagner H,

- Vetter H. New perspectives for synergy research with the “omic”-technologies. *Phytomedicine*. 2009;16(6-7):495-508.
122. Uwaifo F. Evaluation of weight and appetite of adult wistar rats supplemented with ethanolic leaf extract of *Moringa oleifera*. *Biomed Biotechnol Res J*. 2020;4(2):137-40.
123. Uwaifo F, Favour JO. Assessment of the histological changes of the heart and kidneys induced by berberine in adult albino wistar rats. *Matrix Sci Med*. 2020;4(3):70-3.
124. Uwaifo F, John-Ohimai F. Body weight, organ weight, and appetite evaluation of adult albino Wistar rats treated with berberine. *Int J Health Allied Sci*. 2020;9(4):329.
125. Uwaifo F, John-Ohimai F. Dangers of organophosphate pesticide exposure to human health. *Matrix Sci Med*. 2020;4(2):27-31.
126. Uwaifo F, Ngokere A, Obi E, Olaniyan M, Bankole O. Histological and biochemical changes induced by ethanolic leaf extract of *Moringa oleifera* in the liver and lungs of adult wistar rats. *Biomed Biotechnol Res J*. 2019;3(1):57-60.
127. Uwaifo F, Obi E, Ngokere A, Olaniyan MF, Oladeinde BH, Mudiaga A. Histological and biochemical changes induced by ethanolic leaf extract of *Moringa oleifera* in the heart and kidneys of adult wistar rats. *Imam J Appl Sci*. 2018;3(2):59-62.
128. Wilkins CH, Edwards TL, Stroud M, Kennedy N, Jerome RN, Lawrence CE, *et al*. The Recruitment Innovation Center: developing novel, person-centered strategies for clinical trial recruitment and retention. *J Clin Transl Sci*. 2021;5(1):e194.
129. Will Y, McDuffie JE, Olaharski AJ, Jeffy BD, editors. *Drug discovery toxicology: from target assessment to translational biomarkers*. Hoboken: John Wiley & Sons; 2016.
130. Zineh I, Woodcock J. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation. *Clin Pharmacol Ther*. 2013;93(6):515-25.